Influenza Vaccine Market to grow by USD 2.93 billion from 2022 to 2027; North America to account for 54% of market growth - Technavio
NEW YORK, Dec. 13, 2023 /PRNewswire/ -- The influenza vaccine market is expected to grow by USD 2.93 billion from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 6.89% during the forecast period, according to Technavio Research. The market is segmented by distribution channel (hospitals and pharmacies, government and institutional, and others), type (live attenuated influenza vaccines and recombinant influenza vaccines), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). North America is estimated to contribute 54% to the growth of the global market during the forecast period. The presence of public authorities in this region such as the Pan American Health Organization PNGHO, which provides recommendations on vaccination schedules, could be to blame. Some of the most important vaccine products for sale in this region are BOOSTRIX, INFANRIX, Pediarix, BEXSERO, MENVEO, and influenza.
This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a Free PDF Sample Report
Company Profile:
Altimmune Inc., AstraZeneca PLC, Baxter International Inc., BioDiem Ltd, BiondVax Pharmaceuticals Ltd., CSL Ltd., Emergent BioSolutions Inc., F. Hoffmann La Roche Ltd., FluGen Inc., GlaxoSmithKline Plc, Mitsubishi Chemical Group Corp., Novavax Inc., Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, Shijiazhuang Yiling Pharmaceutical Co Ltd., SK Chemicals Co. Ltd., Vaccitech Plc, Vaxart Inc., and Vaxine Pty Ltd.
Altimmune Inc. - The company offers influenza vaccines such as NasoVax.
To gain access to more company profiles available with Technavio, buy the report!
Influenza Vaccine Market: Segmentation Analysis
The market share growth by the hospitals and pharmacies segment will be significant during the forecast period. The administration of the vaccine is under the responsibility of hospitals, particularly in those who are at increased risk for an influenza infection.
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a Free PDF Sample Report
Influenza Vaccine Market: Market Dynamics
Key Driver
Rising awareness about influenza vaccination
Increasing prevalence and incidence of influenza
Initiation of immunization programs and research activities
The Rising awareness about influenza vaccination is a key factor driving market growth. Both government and non-government bodies are taking various initiatives to improve awareness about the disease and its prevention. For example, the CDC conducts National Influenza Vaccination Week (NIVW), a national awareness campaign every year to educate the public about the importance of influenza vaccination. As a result, the awareness campaigns help people to know about the preventive measures available against influenza.
Major Trend
The need for revaccination is one of the major trends in the market. Identify key trends, drivers, and challenges in the market. Download a sample to gain access to this information.
Related Reports:
The Human Vaccine Market size is estimated to grow by USD 29.1 billion at a CAGR of 9.49% between 2023 and 2028.
The global pneumococcal vaccine market size is estimated to grow by USD 2,820.53 million at a CAGR of 5.81% between 2022 and 2027.
What are the key data covered in this influenza vaccine market report?
CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the influenza vaccine market between 2022 and 2027.
Precise estimation of the influenza vaccine market size and its contribution to the market in focus on the parent market
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the influenza vaccine market across North America, Europe, Asia, and ROW
A thorough analysis of the market's competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of influenza vaccine market companies.
ToC:
Executive Summary
Market Landscape
Market Sizing
Historic Market Sizes
Five Forces Analysis
Market Segmentation by Distribution Channel
Market Segmentation by Type
Market Segmentation by Geography
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/influenza-vaccine-market-to-grow-by-usd-2-93-billion-from-2022-to-2027-north-america-to-account-for-54-of-market-growth---technavio-302013755.html
SOURCE Technavio
